New combo therapy shows promise for tough cancers
Disease control
Completed
This study tested a new drug combination (IO102-IO103 plus pembrolizumab) as a first treatment for people with advanced lung, head/neck, or bladder cancer that had spread. The goal was to see if the combo could shrink tumors and delay cancer growth. A total of 63 patients took pa…
Phase: PHASE2 • Sponsor: IO Biotech • Aim: Disease control
Last updated May 01, 2026 15:57 UTC